

CLAIMS

1. Use of an isolated humanized protein binding to human Glycoprotein VI (hGPVI) in the manufacture of a medicament for the treatment of a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 4 to 6 hours to the subject, wherein said isolated humanized protein is an antibody molecule or an antibody fragment, and wherein
 - the variable region of the heavy chain comprises the following CDRs:
 - VH-CDR1:** GYTFTSYNMH (SEQ ID NO: 1);
 - VH-CDR2:** GIYPGNGDTSYNQKFQG (SEQ ID NO: 2); and
 - VH-CDR3:** GTVVGDWYFDV (SEQ ID NO: 3); and
 - the variable region of the light chain comprises the following CDRs:
 - VL-CDR1:** RSSQSLENSNGNTYLN (SEQ ID NO: 4);
 - VL-CDR2:** RVSNRFS (SEQ ID NO: 5); and
 - VL-CDR3:** LQLTHVPWT (SEQ ID NO: 6).
2. The use according to claim 1, wherein the isolated humanized protein is injected.
3. The use according to claim 1 or claim 2, wherein the isolated humanized protein is injected by intravenous infusion.
4. The use according to any one of claims 1 to 3, wherein a dose of humanized protein ranging from about 0.5 mg/kg to about 50 mg/kg is to be administered to the patient.
5. The use according to claim 4, wherein a dose of humanized protein ranging from about 1 mg/kg to about 32 mg/kg is to be administered to the patient.
6. The use according to claim 4 or claim 5, wherein a dose of humanized protein of about 8 mg/kg is to be administered to the patient.

7. The use according to any one of claims **1** to **3**, wherein a dose of humanized protein ranging from about 125 mg to about 2000 mg is to be administered to the patient.
8. The use according to claim **7**, wherein a dose of humanized protein ranging from
5 about 500 mg to about 1000 mg is to be administered to the patient.
9. The use according to any one of claims **1** to **8**, wherein a first bolus of the isolated humanized protein is administered.
10. The use according to claim **9**, wherein said first bolus administration comprises
10 about 20% of the total dosage of the isolated humanized protein to be administered, and wherein said first bolus is administered in about 15 minutes.
11. The use according to any one of claims **1** to **10**, wherein said isolated humanized protein is an antibody molecule selected from the group consisting of a whole antibody, a single chain antibody, a Fv, a Fab or an antibody fragment selected from the group consisting of a unibody, a domain antibody, and a nanobody.
- 15 12. The use according to any one of claims **1** to **11**, wherein said isolated humanized protein is a monovalent antibody.
13. The use according to any one of claims **1** to **12**, wherein the amino acid sequence encoding the heavy chain variable region is SEQ ID NO: 7 and the amino acid sequence encoding the light variable region is SEQ ID NO: 8, or any sequence
20 having an amino acid sequence that shares at least 60% of identity with said SEQ ID NO: 7 or 8.
14. The use according to any one of claims **1** to **13**, wherein said GPVI-related condition is selected from arterial and venous thrombosis, restenosis, acute coronary syndrome, cerebrovascular accidents due to atherosclerosis, critical limb
25 ischemia, cerebral vascular diseases including ischemic stroke, venous thromboembolism diseases, thrombotic microangiopathies and vascular purpura.

15. The use according to any one of claims **1** to **13**, wherein said GPVI-related condition is selected from coronary artery and cerebral artery diseases.
16. The use according to any one of claims **1** to **13**, wherein said GPVI-related condition is a cardiovascular disease selected from atherothrombosis, ischemic events, acute coronary artery syndrome, myocardial infarction, stroke, percutaneous coronary intervention, stenting thrombosis, ischemic restenosis, acute ischemia, chronic ischemia, diseases of the aorta and its branches, peripheral artery disease, venous thrombosis, acute phlebitis, pulmonary embolism, cancer-associated thrombosis, inflammatory thrombosis and thrombosis associated to infection.